ANI | | Posted by Tapatrisha Das, Washington

Researchers at Swansea University found {that a} medication regularly used to deal with kind 2 diabetes may probably be used to deal with autoimmune illnesses.

Academics on the University's Faculty of Medicine, Health and Life Science have discovered that the drug, canagliflozin (also referred to as Invokana), might be used to deal with autoimmune problems comparable to rheumatoid arthritis and systemic lupus erythematosus because it targets T-cells, which kind an integral part of the immune system. Canagliflozin is a drug that controls blood sugar levels in individuals with kind 2 diabetes, nevertheless researchers have discovered an sudden position for the drug involving the human immune system.

Existing analysis has reported that concentrating on T-cell metabolism in autoimmunity can result in therapeutic advantages. T-cells are a kind of white blood cell that assist the body fight infections and diseases, however in autoimmune ailments they've been noticed to assault wholesome tissues.

ALSO READ: The cause of autoimmunity in patients with type 1 Diabetes: Research

The new research, funded by the Medical Research Council and revealed in the present day within the journal Cell Metabolism, discovered that canagliflozin dampens down T-cell activation, suggesting that the drug might be repurposed as a therapy for T-cell pushed autoimmunity.

Dr Nick Jones, senior writer who led the research mentioned: "Our findings are significant as they provide the foundation for the clinical development of canagliflozin for the treatment of certain autoimmune diseases. As the drug is already widely used and has a known safety profile in humans, it could potentially reach clinic quicker than any new drugs developed and bring valuable benefits more swiftly to patients with autoimmune disorders."

Ben Jenkins, first writer and postdoctoral researcher at Swansea mentioned: "Identifying new roles for drugs that are currently being used in other disease settings is an exciting area of research. Given that our research primarily targets the metabolism of immune cells, we hope that the potential therapeutic benefits of our findings are applicable to a wide range of conditions."

The researchers are hopeful that canagliflozin will enter a medical trial to deal with sure autoimmune problems sooner or later. (ANI)

This story has been revealed from a wire company feed with out modifications to the textual content. Only the headline has been modified.